Investigation of immune escape-associated mutations of hepatitis B virus in patients harboring hepatitis B virus drug-resistance mutations

Table 3 Analysis of clinical features of sA159V-positive and sA159V-negative patients

Clinical features	sA159V-positive,n = 270	sA159V-negative,n = 19170	Univariate,P value	Univariate,P	Multivariate,P value	Multivariate , P
Age in year	46.67 ± 12.19	40.72 ± 12.83	0.00	< 0.05	0.00	< 0.05
Gender, male	214 (79.26%)	15477 (80.74%)	0.54	> 0.05	0.97	> 0.05
Genotype, C%/B%	90.00/10.00	84.31/14.82	0.03	< 0.05	0.40	> 0.05
HBV DNA as log10 IU/mL	4.54 (3.18, 6.55)	4.37(2.95, 6.27)	0.09	> 0.05	0.40	> 0.05
ALT in U/L	42 (25, 87)	42 (26, 82)	0.67	> 0.05	0.32	> 0.05
AST in U/L	41 (28, 83)	38 (26,71)	0.33	> 0.05	0.61	> 0.05
TBIL in μmol/L	16.10 (10.95, 25.45)	14.30 (10.40, 22.10)	0.13	> 0.05	0.58	> 0.05
CHE in U/L	5940 (3114, 8091)	6764 (4276, 8469)	0.11	> 0.05	0.87	> 0.05
HBsAg, COI	4987.83 ± 3128.43	5064.50 ± 2931.79	0.05	> 0.05	0.15	> 0.05
Coexistent with ADV-r mutation	41 (15.19%)	1663 (8.68%)	0.00	< 0.05	0.00	< 0.05
Coexistent with LAM-r mutation	97 (35.93%)	5316 (27.73%)	0.00	< 0.05	0.01	< 0.05
Coexistent with ETV-r mutation	20 (7.41%)	868 (4.53%)	0.04	< 0.05	0.40	> 0.05

ADV-r: Adefovir resistance; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; CHE: Cholinesterase; COI: Cut-off index; DNA: Deoxyribonucleic acid; ETV-r: Entecavir resistance; HBsAg: Hepatitis B surface antigen; HBV: Hepatitis B virus; LAM-r: Lamivudine resistance; TBIL: Total bilirubin.